AnalystsMatthew BieglerMatthew Biegler's Stock Forecasts
AnalystsMatthew Biegler
Sectors:
Industries:
Analyst Ranking
Top 17%
#862 out of 5143 analysts
Average Return
+10.7%
Win Rate
40%38 out of 94
Risk vs Reward
Poor
Good
Matthew Biegler's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Olema Pharmaceuticals IncOLMA | +646.47% | $4.11 | $30.68 | 2025-03-18 - 2025-12-10 | Buy |
Olema Pharmaceuticals IncOLMA | +581.78% | $4.50 | $30.68 | 2025-05-13 - 2025-12-10 | Buy |
Olema Pharmaceuticals IncOLMA | +387.76% | $6.29 | $30.68 | 2025-09-02 - 2025-12-10 | Buy |
Fate Therapeutics IncFATE | +222.98% | $24.80 | $80.10 | 2020-04-05 - 2021-04-06 | Buy |
Oric Pharmaceuticals IncORIC | +202.61% | $4.99 | $15.10 | 2023-03-15 - 2024-03-15 | Buy |
Matthew Biegler Analyst Color
Get additional color on Matthew Biegler's coverage of popular stocks
Matthew Biegler's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ascentage Pharma Group InternationalAAPG | 1 | Buy | $45.00 | +52.65% | Initiates Coverage On | 7 days ago |
Olema Pharmaceuticals IncOLMA | 8 | Buy | $45.00 | +46.68% | Maintains | 23 days ago |
Oric Pharmaceuticals IncORIC | 6 | Buy | $15.00 | +50.00% | Maintains | a month ago |
Bridgebio Oncology Therapeutics IncBBOT | 2 | Buy | $22.00 | +70.81% | Maintains | a month ago |
Nurix Therapeutics IncNRIX | 3 | Buy | $28.00 | +42.78% | Maintains | 2 months ago |
Acrivon Therapeutics IncACRV | 4 | Buy | $8.00 | +205.34% | Maintains | 4 months ago |
Cytomx Therapeutics IncCTMX | 1 | Buy | $7.00 | +79.49% | Initiates Coverage On | 4 months ago |
Allogene Therapeutics IncALLO | 2 | Buy | $9.00 | +508.11% | Maintains | 7 months ago |
Vor Biopharma IncVOR | 7 | Buy | $160.00 | +1,448.89% | Reiterates | 9 months ago |
Arvinas IncARVN | 5 | Buy | $45.00 | +246.69% | Maintains | 10 months ago |
Gilead Sciences IncGILD | 1 | Buy | $115.00 | N/A | Reiterates | a year ago |
Ideaya Biosciences IncIDYA | 5 | Buy | $53.00 | N/A | Reiterates | a year ago |
Tyra Biosciences IncTYRA | 6 | Buy | $33.00 | N/A | Maintains | a year ago |
Zentalis Pharmaceuticals IncZNTL | 7 | Buy | $20.00 | N/A | Reiterates | a year ago |
Relay Therapeutics IncRLAY | 5 | Buy | $24.00 | N/A | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 5 | Buy | $125.00 | N/A | Maintains | a year ago |
Cartesian Therapeutics IncRNAC | 3 | Buy | $50.00 | N/A | Reiterates | a year ago |
Fulcrum Therapeutics IncFULC | 5 | Buy | $14.00 | N/A | Maintains | 2 years ago |
Alpine Immune Sciences IncALPN | 1 | Buy | $44.00 | N/A | Reiterates | 2 years ago |
Medicenna Therapeutics CorpMDNAF | 3 | Buy | $3.00 | N/A | Maintains | 2 years ago |
Aptose Biosciences IncAPTOF | 5 | Buy | $450.00 | N/A | Maintains | 2 years ago |
Ambrx Biopharma IncAMAM | 1 | Buy | $30.00 | N/A | Initiates Coverage On | 3 years ago |
Alphaton Capital CorpATON | 1 | Buy | $360.00 | N/A | Maintains | 3 years ago |
Nkarta IncNKTX | 2 | Buy | $36.00 | N/A | Maintains | 3 years ago |
Celularity IncCELU | 1 | Buy | $90.00 | N/A | Initiates Coverage On | 4 years ago |
Turning Point Therapeutics IncTPTX | 3 | Buy | $105.00 | N/A | Maintains | 4 years ago |
Fate Therapeutics IncFATE | 1 | Buy | $34.00 | N/A | Maintains | 6 years ago |
Q32 Bio IncQTTB | 1 | Buy | $576.00 | N/A | Upgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.